High Blood Pressure


Key Messages of 2024 ESC Guidelines for High BP

The number of individuals with high blood pressure (BP) is increasing worldwide. The trajectory of BP control appears to be worsening in North America, some European countries, and elsewhere around the world. The risk for cardiovascular diseases (CVD) attributable to BP is on a continuous log-linear exposure variable scale, not […]


BP Remission in Older Adults with High BP

An observational analysis found that many of older adults with high blood pressure (BP) could be reversed without the intervention of drug treatment in the first few years after diagnosis, and the remission was associated with a lower risk of cardiovascular disease (CVD). The analysis included 2760 participants aged 33–99 […]


Salt Substitute May Reduce High Blood Pressure

A post hoc analysis among older adults with normal blood pressure (BP) in a multicenter, cluster-randomized trial in China suggested that replacing usual salt with a salt substitute (62.5% NaCl, 25% KCl, and 12.5% flavorings) may reduce high BP incidence without increasing hypotension episodes. The analysis included 611 older adults […]


Causal Effects of Lipids on High BP

A Mendelian randomization study provides genetic evidence for the causal effects of lipids on blood pressure (BP) indicators. Based on large-scale genome-wide association study summary data, genetically predicted triglycerides (TG) were the most likely causal factor among the major lipids to increase systolic blood pressure (SBP) and diastolic blood pressure […]


SBP <130 mmHg Beneficial for Young-Older Patients

The secondary analysis of a multicenter, randomized, controlled trial in China suggested that maintaining systolic blood pressure (SBP) at <130 mmHg offers additional cardiovascular benefits among young-older patients with high blood pressure. The trial enrolled 8511 young-older (60–80 years) hypertensive patients without prior stroke to compare the intensive treatment (SBP […]


Heterogeneity in BP-Lowering Effects of 4 Drugs

A Swedish randomized, double-blind, repeated crossover trial revealed substantial heterogeneity in blood pressure (BP) response to drug therapy for high BP. There were 280 participants with grade 1 high BP at low risk for cardiovascular events (54% men; mean age, 64 years). Each participant was randomized to treatment with 4 […]